ARBs and target organ protection

References

• McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56(5): 847–69
   Google Scholar
• McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55(5): 713–8
   PubMed Web of Science ®Google Scholar
• Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59(5): 1187–206
   PubMed Web of Science ®Google Scholar
• Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51(5): 820–45 [Erratum, Drugs 1996; 52(4): 540]
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62(9): 1345–53 [Erratum, Drugs 2002; 62(13): 1852]
   PubMed Web of Science ®Google Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61(10): 1501–29
   PubMed Web of Science ®Google Scholar
• Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54(2): 299–311
   PubMed Web of Science ®Google Scholar
• Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32(10): 1060–6
   Web of Science ®Google Scholar
• Hansson L, Smith DH, Reeves R, et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 2000; 160(11): 1654–8
   PubMedGoogle Scholar
• Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89(2A): 3–9A
   PubMed Web of Science ®Google Scholar
• Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12(2): 70–88
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19(6): 1167–76
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27(Suppl 1): 865–7
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–9
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6): 672–8
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361 (9352): 117–24 [Erratum, Lancet 2003; 361(9364): 1230]
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360(9335): 752–60
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893–906 [Erratum, N Engl J Med 2004; 350(2): 203]
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349(9054): 747–52
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–7
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667–75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–66
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362(9386): 767–71
   PubMed Web of Science ®Google Scholar
• Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004; 44(4): 406–13
   Google Scholar